Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Share-based Compensation (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Share-based Compensation readings, the most recent being $26.6 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 38.37% to $26.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $87.4 million, a 2.95% increase, with the full-year FY2025 number at $87.4 million, up 2.95% from a year prior.
  • Share-based Compensation hit $26.6 million in Q4 2025 for Amicus Therapeutics, up from $18.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $34.9 million in Q1 2023 to a low of $11.7 million in Q2 2021.
  • Median Share-based Compensation over the past 5 years was $18.1 million (2023), compared with a mean of $19.6 million.
  • The widest YoY moves for Share-based Compensation: up 61.59% in 2021, down 25.57% in 2021.
  • Amicus Therapeutics' Share-based Compensation stood at $13.9 million in 2021, then surged by 33.93% to $18.6 million in 2022, then decreased by 2.85% to $18.1 million in 2023, then rose by 6.2% to $19.2 million in 2024, then soared by 38.37% to $26.6 million in 2025.
  • The last three reported values for Share-based Compensation were $26.6 million (Q4 2025), $18.1 million (Q3 2025), and $17.6 million (Q2 2025) per Business Quant data.